Advanced search
Add to list

Comprehensive pharmacological profiling in neuroblastoma cell lines using Deep Coverage Microscopy (DCM)

Author
Organization
Abstract
Chemoresistance is a major impediment to successful treatment of a growing number of cancer entities. This phenomenon can be circumvented through highly selective and efficient drugging of molecular targets and pathways implicated in the chemoresistance phenotype. We have recently discovered that MYC(N)-driven tumors show strong upregulation of genes involved in replicative stress (RS)-induced DNA damage repair (DDR). Thus, exploiting this pathway may offer a novel entry point for combinatorial chemotherapy. However, limited knowledge on drug-gene-phenotype interactions complicates rational selection of promising compounds. To address this topic in a systematic manner, we have established a high-content microscopy-based compound-screening assay that provides a holistic readout on DNA damage, cell morphology and cellular stress response. We have validated the approach using compounds that are known to induce DNA damage or replicative stress in a selected panel of neuroblastoma cell lines with different MYCN background. We are now applying it to assess interactions between these compounds and a selected gene set involved in RS/DDR. In doing so, we expect to reveal common modes of action between selected compounds and to infer putative synergies for combinatorial treatments modulating the genes involved in RS and/or DDR. Thus, with our work we aim at devising a more powerful, robust and integrative approach for assessing synthetic lethality. This will be a key strategy for more efficient killing of tumors and for use in patients in which conventional methods no longer show effect.

Citation

Please use this url to cite or link to this publication:

MLA
Zanotti, Sofia, et al. “Comprehensive Pharmacological Profiling in Neuroblastoma Cell Lines Using Deep Coverage Microscopy (DCM).” RBSM Meeting 2019, Abstracts, 2019.
APA
Zanotti, S., Verschuuren, M., Hogarty, M. D., Durinck, K., Vanhauwaert, S., De Vos, W. H., & Speleman, F. (2019). Comprehensive pharmacological profiling in neuroblastoma cell lines using Deep Coverage Microscopy (DCM). In RBSM Meeting 2019, Abstracts. Louvain-la-Neuve, Belgium.
Chicago author-date
Zanotti, Sofia, Marlies Verschuuren, Michael D. Hogarty, Kaat Durinck, Suzanne Vanhauwaert, Winnok H. De Vos, and Franki Speleman. 2019. “Comprehensive Pharmacological Profiling in Neuroblastoma Cell Lines Using Deep Coverage Microscopy (DCM).” In RBSM Meeting 2019, Abstracts.
Chicago author-date (all authors)
Zanotti, Sofia, Marlies Verschuuren, Michael D. Hogarty, Kaat Durinck, Suzanne Vanhauwaert, Winnok H. De Vos, and Franki Speleman. 2019. “Comprehensive Pharmacological Profiling in Neuroblastoma Cell Lines Using Deep Coverage Microscopy (DCM).” In RBSM Meeting 2019, Abstracts.
Vancouver
1.
Zanotti S, Verschuuren M, Hogarty MD, Durinck K, Vanhauwaert S, De Vos WH, et al. Comprehensive pharmacological profiling in neuroblastoma cell lines using Deep Coverage Microscopy (DCM). In: RBSM Meeting 2019, Abstracts. 2019.
IEEE
[1]
S. Zanotti et al., “Comprehensive pharmacological profiling in neuroblastoma cell lines using Deep Coverage Microscopy (DCM),” in RBSM Meeting 2019, Abstracts, Louvain-la-Neuve, Belgium, 2019.
@inproceedings{8655584,
  abstract     = {Chemoresistance is a major impediment to successful treatment of a growing number of cancer entities. This phenomenon can be circumvented through highly selective and efficient drugging of molecular targets and pathways implicated in the chemoresistance phenotype. We have recently discovered that MYC(N)-driven tumors show strong upregulation of genes involved in replicative stress (RS)-induced DNA damage repair (DDR). Thus, exploiting this pathway may offer a novel entry point for combinatorial chemotherapy. However, limited knowledge on drug-gene-phenotype interactions complicates rational selection of promising compounds.
To address this topic in a systematic manner, we have established a high-content microscopy-based compound-screening assay that provides a holistic readout on DNA damage, cell morphology and cellular stress response. We have validated the approach using compounds that are known to induce DNA damage or replicative stress in a selected panel of neuroblastoma cell lines with different MYCN background. We are now applying it to assess interactions between these compounds and a selected gene set involved in RS/DDR. In doing so, we expect to reveal common modes of action between selected compounds and to infer putative synergies for combinatorial treatments modulating the genes involved in RS and/or DDR.
Thus, with our work we aim at devising a more powerful, robust and integrative approach for assessing synthetic lethality. This will be a key strategy for more efficient killing of tumors and for use in patients in which conventional methods no longer show effect.},
  author       = {Zanotti, Sofia and Verschuuren, Marlies and Hogarty, Michael D. and Durinck, Kaat and Vanhauwaert, Suzanne and De Vos, Winnok H. and Speleman, Franki},
  booktitle    = {RBSM Meeting 2019, Abstracts},
  language     = {eng},
  location     = {Louvain-la-Neuve, Belgium},
  pages        = {1},
  title        = {Comprehensive pharmacological profiling in neuroblastoma cell lines using Deep Coverage Microscopy (DCM)},
  year         = {2019},
}